dipeptidyl peptidase-4 inhibitor

dipeptidyl peptidase-4 inhibitor. Dipeptidyl peptidase-4 inhibitors, commonly known as DPP-4 inhibitors or gliptins, are a class of oral antidiabetic medications. They function by enhancing the body's own incretin system, leading to improved glucose control in patients with type 2 diabetes mellitus. Their development marked a significant advance in diabetes management, offering a well-tolerated treatment option with a low risk of hypoglycemia.

Mechanism of action

These agents work by selectively inhibiting the enzyme dipeptidyl peptidase-4. This enzyme rapidly degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking DPP-4, the inhibitors prolong the activity of endogenous GLP-1 and GIP. This results in increased glucose-dependent insulin secretion from pancreatic beta cells and suppressed glucagon release from pancreatic alpha cells. The glucose-dependent nature of this mechanism underlies the low incidence of hypoglycemia associated with this drug class.

Medical uses

DPP-4 inhibitors are indicated for the treatment of hyperglycemia in type 2 diabetes mellitus. They are used as monotherapy or, more commonly, in combination with other antidiabetic agents like metformin, sulfonylurea, or thiazolidinedione. They are often prescribed when metformin alone is insufficient or not tolerated. Their efficacy and safety profile make them suitable for older patients and those with chronic kidney disease, with dose adjustments required for certain agents like sitagliptin and saxagliptin. They are not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.

Adverse effects

Overall, DPP-4 inhibitors are considered to have a favorable tolerability profile. Common adverse reactions may include nasopharyngitis, headache, and upper respiratory tract infection. There has been ongoing scrutiny by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency regarding potential risks. These include a possible increased risk of acute pancreatitis, heart failure (notably with saxagliptin), and severe arthralgia. Post-marketing surveillance has also reported rare cases of bullous pemphigoid and angioedema.

Pharmacokinetics

Members of this class are generally administered orally and exhibit good bioavailability. They are primarily eliminated via renal excretion (e.g., sitagliptin, vildagliptin) or hepatic metabolism (e.g., saxagliptin, linagliptin). This difference in elimination pathways is crucial for dosing in patients with hepatic impairment or renal impairment. Most have a relatively long half-life, allowing for once-daily dosing, which supports medication adherence. Drug interactions are minimal, though saxagliptin metabolism is affected by potent CYP3A4 inhibitors like ketoconazole.

Examples

Several DPP-4 inhibitors have been approved for clinical use worldwide since the introduction of sitagliptin. Other prominent members include vildagliptin, saxagliptin, linagliptin, and alogliptin. Anagliptin, teneligliptin, and gemigliptin are also available in specific markets such as Japan and South Korea. Each agent has distinct pharmacokinetic properties, but they share the core mechanism of DPP-4 inhibition. Fixed-dose combination tablets with metformin are widely marketed to simplify treatment regimens.

History and development

The development of DPP-4 inhibitors followed the discovery and characterization of the incretin effect and the role of DPP-4 in the 1990s. Research at institutions like Novartis and Merck & Co. was pivotal. Sitagliptin, developed by Merck & Co., received approval from the U.S. Food and Drug Administration in 2006, becoming the first in its class. Subsequent approvals for vildagliptin (Novartis) and others followed rapidly. Large cardiovascular outcome trials, such as SAVOR-TIMI 53 and EXAMINE, were later conducted to assess cardiovascular safety, a requirement instituted by the FDA after concerns with rosiglitazone. Category:Antidiabetic drugs Category:Enzyme inhibitors